SCHEMBL3873986

SCHEMBL3873986

CC(c1ccc(CCNC(=O)c2ccc(-c3ccc(OC(F)(F)F)cc3)cc2)cc1)N1CCCC1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 6/20 0.53
GCGR P47871 7/20 0.51
MCHR1 Q99705 3/20 0.50
CHRM1 P11229 2/20 0.49
CHRM2 P08172 1/20 0.49
CYP2D6 P10635 1/20 0.48
HTR2A P28223 1/20 0.48
ALDH1A1 P00352 1/20 0.48
FABP2 P12104 1/20 0.48
PPARG P37231 1/20 0.48
PPARD Q03181 1/20 0.48
PPARA Q07869 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
OPRM1 P35372 1/20 0.48
OPRD1 P41143 1/20 0.48
OPRK1 P41145 1/20 0.48
CHRM4 P08173 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3867758 0.99 TRPV1 (0.52) TRPV1GCGRMCHR1CHRM1CHRM2
SCHEMBL3871933 0.99 TRPV1 (0.52) TRPV1GCGRMCHR1CHRM1CHRM2
SCHEMBL3868881 0.93 TRPV1 (0.51) TRPV1GCGRCHRM1CHRM2ALDH1A1
SCHEMBL3873309 0.88 MCHR1 (0.53) MCHR1CHRM1CYP2D6HTR2AALDH1A1
SCHEMBL3877263 0.88 KDM4E (0.56) MCHR1CHRM1CYP2D6HTR2AALDH1A1
SCHEMBL3870597 0.87 MCHR1 (0.53) MCHR1CHRM1CYP2D6HTR2AALDH1A1
SCHEMBL3872342 0.87 MCHR1 (0.53) MCHR1CHRM1CYP2D6HTR2AALDH1A1
SCHEMBL3868681 0.87 KDM4E (0.55) MCHR1CHRM1CYP2D6HTR2AALDH1A1
SCHEMBL3871649 0.87 KDM4E (0.55) MCHR1CHRM1CYP2D6HTR2AALDH1A1
SCHEMBL3881228 0.86 MCHR1 (0.67) MCHR1CHRM1CYP2D6HTR2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 US disclosed
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 US disclosed
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 US disclosed
US-20060128690-A1 Amine derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-15 US disclosed
EP-1593667-A1 AMINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2005-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128690-A1 Amine derivative MC1R, MC2R, MC4R TRPV1 2435/4885GCGR 112/4885MCHR1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.